Yuken India Limited (BOM:522108)

Verve Therapeutics Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	25.71	101.76	24.82	36.76	58.46
Trading Asset Securities	-	0.16	-	-	-
Cash & Short-Term Investments	25.71	101.91	24.82	36.76	58.46
Cash Growth	-74.77%	310.59%	-32.48%	-37.12%	499.29%
Accounts Receivable	1,164	1,196	1,148	1,184	922.09
Other Receivables	-	2.94	5.4	2.34	1.9
Receivables	1,168	1,203	1,158	1,191	924.44
Inventory	935.39	860.63	853.81	1,692	1,929
Prepaid Expenses	-	27.58	24.69	24.92	10.16
Other Current Assets	111.16	187.79	158.49	130.67	119.52
Total Current Assets	2,240	2,381	2,219	3,075	3,041
Property, Plant & Equipment	2,566	2,038	1,777	1,516	1,272
Long-Term Investments	115.09	81.69	80.01	51.08	44.72
Goodwill	25.79	25.79	25.79	25.79	25.79
Other Intangible Assets	31.5	30.06	34.54	41.92	44.62
Long-Term Deferred Tax Assets	15.67	17.1	29.42	24.34	21.87
Long-Term Deferred Charges	-	0.24	0.48	0.7	-
Other Long-Term Assets	248.32	235.86	239.41	84.38	51.53
Total Assets	5,244	4,813	4,409	4,823	4,502
Accounts Payable	566.41	570.57	784.94	689.52	613.44
Accrued Expenses	52.23	122.56	107.39	107.43	99.73
Short-Term Debt	-	614.2	944.2	835.46	773.24
Current Portion of Long-Term Debt	825.54	74.69	92.16	115.75	122.56
Current Portion of Leases	11.98	6.08	6.18	4.96	1.7
Current Income Taxes Payable	-	9.75	8.19	2.35	4.2
Current Unearned Revenue	-	209.16	158.44	875.65	782.05
Other Current Liabilities	474.98	200.17	49.82	41.97	45.88
Total Current Liabilities	1,931	1,807	2,151	2,673	2,443
Long-Term Debt	60.61	80.44	141.05	154.47	161.37
Long-Term Leases	95.53	6.27	8.19	7.27	4.08
Long-Term Deferred Tax Liabilities	107.48	99.44	91.63	52.29	39.59
Other Long-Term Liabilities	0.74	0.81	1.64	0.35	48.63
Total Liabilities	2,232	2,018	2,415	2,914	2,722
Common Stock	130	130	120	120	120
Additional Paid-In Capital	-	619	-	-	-
Retained Earnings	-	2,042	1,869	1,785	1,656
Comprehensive Income & Other	2,882	4.24	4.24	4.24	4.24
Total Common Equity	3,012	2,795	1,993	1,909	1,781
Minority Interest	0.55	0.73	1.04	0.22	-0.34
Shareholders' Equity	3,012	2,796	1,994	1,909	1,780
Total Liabilities & Equity	5,244	4,813	4,409	4,823	4,502
Total Debt	993.67	781.68	1,192	1,118	1,063
Net Cash (Debt)	-967.96	-679.77	-1,167	-1,081	-1,004
Net Cash Per Share	-74.46	-53.29	-97.25	-90.10	-83.71
Filing Date Shares Outstanding	13	13	12	12	12
Total Common Shares Outstanding	13	13	12	12	12
Working Capital	308.62	573.74	68.04	402.12	598.68
Book Value Per Share	231.66	215.00	166.09	159.07	148.39
Tangible Book Value	2,954	2,739	1,933	1,841	1,710
Tangible Book Value Per Share	227.25	210.71	161.07	153.43	142.52
Land	-	248.79	248.79	248.79	248.79
Buildings	-	690.36	614.84	465.58	352.9
Machinery	-	1,528	1,306	1,047	881.62
Construction In Progress	-	197.48	116.4	159.15	125.59

Source: S&P Global Market Intelligence. Standard template. Financial Sources.